scholarly journals A comparative analysis of the transplant potential of umbilical cord blood versus mobilized peripheral blood stem cells.

1997 ◽  
Vol 64 (4) ◽  
pp. 307-313 ◽  
Author(s):  
Seiji Gomi ◽  
Setsuo Hasegawa ◽  
Kazuo Dan ◽  
Ichiji Wakabayashi
Keyword(s):  
Stem Cells ◽  
Comparative Analysis ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
Mobilized Peripheral Blood

Granulocyte-Derived Cationic Peptides (GDCPs) Present in Leucophoresis Products Enhance Homing of Hematopoietic Stem Cells (HSCs) to SDF-1 Gradient; Potential Implications for Accelerated Recovery of Hematopoiesis After Transplantation of Mobilized Peripheral Blood Stem Cells (PBSC).

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 371-371
Author(s):  
HakMo Lee ◽  
Wan Wu ◽  
Marcin Wysoczynski ◽  
Magdalena Kucia ◽  
Mary J. Laughlin ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Peripheral Blood ◽  
Ex Vivo ◽  
Cationic Peptides ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells ◽  
Anaphylatoxin C3a ◽  
Mobilized Peripheral Blood

Abstract Abstract 371 Current strategies to accelerate hematopoietic reconstitution after transplantation, include transplantation of greater numbers of HSC or ex vivo expansion of harvested HSC before transplant. However, the number of HSC availabel for allogeneic or autologous transplantation can be low (e.g., umbilical cord blood, poor mobilizers) and strategies to expand HSC and maintain equivalent engraftment capability ex vivo are limited. We reported that some compounds present in leucopheresis products [(e.g., platelet-derived microparticles (Blood 2001, 98: 3143)] and some complement cascade cleavage fragments, e.g., anaphylatoxin C3a (Blood 2005, 101, 3784), enhance the homing responses of HSC to SDF-1 gradient. We recently noted that small cationic peptides released from activated granulocytes (beta2-defensin and cathelicidin) positively prime responsiveness of murine and human HSC to SDF-1 gradient (Leukemia 2009; in press). Accordingly, both compounds enhanced transwell migration of HSC to low threshold doses of SDF-1. This phenomenon was not receptor-dependent, as agonists of membrane receptors that may bind beta2-defensin (FPRL-1), cathelicidin (CCR6) - FPRL-1 agonist, and MIP-3alpha, respectively, did not show similar priming effects. This could be explained by affected distribution of membrane lipids by cationic peptides. In support of this notion, an inhibitor of cell membrane raft formation (methyl-b-cyclodextran) inhibited the priming effect of both compounds, indicating this effect is dependent on CXCR4 incorporation into lipid rafts. Direct confocal analysis of CXCR4 and lipid raft colocalization in the presence or absence of cationic peptides confirmed these findings. Because leucopheresis products are enriched in activated granulocytes that release beta2-defensin and cathelicidin, we tested whether this may explain why mobilized peripheral blood stem cells (PBSC) engraft faster compared to HSC isolated directly from bone marrow (BM) in a murine BM transplant model. Accordingly, syngeneic BMMNCs were exposed ex vivo to beta2-defensin or cathelicidin for 30 minutes and subsequently transplanted into lethally irradiated recipients. We noted that animals transplanted with BM cells primed by those cationic peptides showed accelerated recovery of platelets and neutrophils by ∼3-5 days compared to unprimed control cells. We envision that small cationic peptides, which primarily possess antimicrobial functions and are harmless to mammalian cells, could be clinically applied to prime human HSC before transplantation. This novel approach would be particularly important in cord blood transplantation, where the number of HSC availabel for transplantation is usually limited. We postulate that this promising strategy warrants further investigations. Disclosures: No relevant conflicts of interest to declare.

scholarly journals HCMV Infection of Humanized Mice after Transplantation of G-CSF–Mobilized Peripheral Blood Stem Cells from HCMV-Seropositive Donors

2014 ◽  
Vol 20 (1) ◽  
pp. 132-135 ◽  
Author(s):  
Morgan Hakki ◽  
Devorah C. Goldman ◽  
Daniel N. Streblow ◽  
Kimberly L. Hamlin ◽  
Craig N. Krekylwich ◽  
...  
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Hcmv Infection ◽  
Humanized Mice ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
Mobilized Peripheral Blood

scholarly journals From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain

2017 ◽  
Vol 83 (1-2) ◽  
pp. 205-213 ◽  
Author(s):  
Priya F Maillacheruvu ◽  
Lauren M Engel ◽  
Isaiah T Crum ◽  
Devendra K Agrawal ◽  
Eric S Peeples
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Injured Brain ◽  
Blood Stem Cells ◽  
Cord Blood Stem Cells

scholarly journals Application of Umbilical Cord Blood Stem Cells in Regenerative Medicine

2014 ◽  
Vol 6 (3) ◽  
pp. 115
Author(s):  
Anna Meiliana ◽  
Andi Wijaya
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Embryonic Stem ◽  
Hematopoietic Stem ◽  
Blood Stem Cells ◽  
Induced Pluripotent ◽  
Nerve Muscle

BACKGROUND: Since the first umbilical cord blood (UCB) transplant, performed 25 years ago, UCB banks have been established worldwide for the collection and cryopreservation of UCB for autologous and allogeneic transplants.CONTENT: Much has been learned in a relatively short time on the properties of UCB hematopoietic progenitors and their clinical application. More interestingly, non-hematopoietic stem cells have been isolated from UCB. These cells can be grown and differentiated into various tissues including bone, cartilage, liver, pancreas, nerve, muscle and so on. The non-hematopoietic stem cells have an advantage over other sources of stem cells, such as embryonic stem cells or induced pluripotent stem cells, because their supply is unlimited, they can be used in autologous or allogeneic situations, they need minimal manipulation and they raise no ethical concerns. Future studies will test the potential of UCB cells for the treatment of several diseases including, among other possibilities, diabetes, arthritis, burns, neurological disorder and myocardial infarction.SUMMARY: In addition to hematopoietic stem cells, UCB contain a large number of non-hematopoietic stem cells. In the absence of ethical concern, the unlimited supply of UCB cells explains the increasing interest of using UCB for developing regenerative medicine.KEYWORDS: UCB, transplantation, UCB bank, HSC, MSC, CD34, CD133, VSEL

Sign in / Sign up

Export Citation Format

Share Document